SCHEMBL24326465

SCHEMBL24326465

CCCc1ccc(CN2CC(=O)c3cccnc3C2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.40
MAPT P10636 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
ADRA1D P25100 2/20 0.40
ADRA1A P35348 2/20 0.40
ADRA1B P35368 2/20 0.40
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTR7 P34969 1/20 0.37
HTR6 P50406 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29570967 0.85 TDP1 (0.50) TP53MAPTRAB9ASMN1; SMN2ADRA1D
SCHEMBL24326772 0.85 TDP1 (0.50) TP53MAPTRAB9ASMN1; SMN2ADRA1D
SCHEMBL17260672 0.67 CASP3 (0.59) ADRA1DADRA1AADRA1BALDH1A1CA1
SCHEMBL30059278 0.65 NPC1 (0.52) TP53MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL16755492 0.65 ALDH1A1 (0.69) TP53MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL16769889 0.65 ALDH1A1 (0.69) TP53MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL16755491 0.65 ALDH1A1 (0.69) TP53MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL21162380 0.64 NPC1 (0.55) TP53MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL30451947 0.64 SIGMAR1 (0.46) TP53MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL3715438 0.64 SIGMAR1 (0.46) TP53MAPTRAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076625-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 WO disclosed